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Abstract: Background: It has been previously demonstrated that
patients with reﬂux esophagitis exhibit a signiﬁcant impairment in the
secretion of salivary protective components versus controls. However,
the secretion of salivary protective factors in patients with nonerosive
reﬂux disease (NERD) is not explored. The authors therefore studied the
secretion of salivary volume, pH, bicarbonate, nonbicarbonate glyco-
conjugate, protein, epidermal growth factor (EGF), transforming growth
factor alpha (TGF-a) and prostaglandin E2 in patients with NERD and
compared with the corresponding values in controls (CTRL).
Methods: Salivary secretion was collected during basal condition,
mastication and intraesophageal mechanical (tubing, balloon) and
chemical (initial saline, acid, acid/pepsin, ﬁnal saline) stimulations,
respectively, mimicking the natural gastroesophageal reﬂux.
Results: Salivary volume, protein and TGF-a outputs in patients with
NERD were signiﬁcantly higher than CTRL during intraesophageal
mechanical (P , 0.05) and chemical stimulations (P , 0.05). Salivary
bicarbonate was signiﬁcantly higher in NERD than CTRL group during
intraesophageal stimulation with both acid/pepsin (P , 0.05) and saline
(P , 0.01). Salivary glycoconjugate secretion was signiﬁcantly higher
in the NERD group than the CTRL group during chewing (P , 0.05),
mechanical (P , 0.05) and chemical stimulation (P , 0.01). Salivary
EGF secretion was higher in patients with NERD during mechanical
stimulation (P, 0.05). Conclusions: Patients with NERD demonstrated
a signiﬁcantly stronger salivary secretory response in terms of volume,
bicarbonate, glycoconjugate, protein, EGF and TGF-a than asymptom-
atic controls. This enhanced salivary esophagoprotection is potentially
mediating resistance to the development of endoscopic mucosal
changes by gastroesophageal reﬂux.
Key Indexing Terms: Nonerosive reﬂux disease; Salivary protection;
Bicarbonate; Glycoconjugate; Epidermal growth factor. [Am J Med Sci
2015;349(5):385–391.]
G astroesophageal reﬂux disease (GERD) is a highly prevalentdisease in the western world and affects approximately up to
20% of adults and nearly 25 million experience heartburn on
a daily basis.1–3 Heartburn is elicited by the contact of the esoph-
ageal mucosal chemoreceptors with aggressive factors, predom-
inantly acid, pepsin and bile components on the luminal
perimeter of the esophageal mucosa during the episodes of gas-
troesophageal reﬂux.4 Response within chemoreceptors is sub-
sequently conveyed through the afferent autonomic ﬁbers of the
esophagosalivary reﬂex pathway, resulting in its modulatory
impact on the secretory function of salivary glands.5,6 Salivary
secretion of water and inorganic components (electrolytes and
buffers) is mediated predominantly by parasympathetic pathways
whereas secretion of organic components (proteins, glycoconju-
gates and peptides) by sympathetic pathways.7–10
Salivary secretion combined with a local secretory
response within the esophageal submucosal mucous glands
deﬁnes the quality and the quantity of the esophageal pre-
epithelial barrier, which is pivotal in the maintenance of the
integrity of the esophageal epithelium.10–14 Therefore, heart-
burn, although often worrisome for the patient, is a beneﬁcial
symptom if it is capable of inducing an adequate salivary secre-
tory response facilitating neutralization and inactivation of the
aggressive factors within the esophageal lumen and thus restor-
ing near-neutral pH within the esophageal lumen.12,15,16
The majority of patients with GERD (up to 60%) have
no visible erosive abnormalities during standard endoscopic
examination, and this subgroup is deﬁned as nonerosive
reﬂux disease (NERD).17,18 NERD is a condition in which
typical reﬂux symptoms, heartburn and regurgitation are
deﬁned as troublesome in patients with negative endoscopy.
The absence of visible lesions on endoscopy and the presence
of troublesome reﬂux-associated (acidic, weakly acidic or
non-acid reﬂux) symptoms are the 2 key factors for the def-
inition of NERD. This clinical entity also requires abnormal
impedance-pH monitoring for its diagnosis.19 It has been
demonstrated previously by Rourk that patients with reﬂux
esophagitis (RE) fail to illicit a vigorous secretory response of
salivary epidermal growth factor (EGF) during intraesopha-
geal mechanical and chemical stimulations.20 The amount of
secretion of salivary protective factors in patients with NERD
remains unknown. It is legitimate to surmise that a vigorous
and protective salivary secretory response in terms of its
major protective factors to an aggressive intraesophageal
challenge in patients with NERD may prevent endoscopic
mucosal injury.
MATERIALS AND METHODS
Subjects
The study was approved by the Human Subject
Committee and conducted on 33 asymptomatic volunteers
(15 women and 18 men; mean age of 39 years; range, 26–56
years) and 10 white patients (4 women and 6 men; mean age
of 40 years; range, 27–64 years) with a history of GERD
(heartburn as a predominant symptom) conﬁrmed by 24-
hour pH monitoring and grossly normal endoscopy. Informed
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consent was obtained from all subjects. All subjects were not
afﬂicted with any acute illness, did not use tobacco, alcohol or
chewing gum, did not receive any medications including acid
suppressive therapies and antisecretory medications 14 days
before the procedure, and never had any dysfunction of
mastication.
Salivary Sample Collection
Subjects expectorated all saliva collected in their mouth
every 10 seconds and were instructed not to swallow during the
procedure. The salivary samples were sequentially collected on
ice during the same time of the day for each subject as follows:
(1) basal saliva during the ﬁrst 10 minutes, (2) saliva produced
during stimulation by paraﬁlm chewing (mastication) during the
following 5 minutes, (3) saliva produced by tubing following the
placement of the intraesophageal catheter during 2 consecutive
1.5-minute intervals, (4) saliva produced following inﬂation of
both intraesophageal balloons during 2 consecutive 1.5-minute
intervals and (5) saliva produced during the esophageal perfusion
with initial saline (NaCl), hydrochloric acid (HCl), HCl/pepsin
and ﬁnal saline consecutively, 4 samples each totaling 16
consecutive 1.5-minute intervals. The order of perfusions is very
important as we go from initial saline, which represents “physi-
ological” neutral pH reﬂux, followed by HCl where hydrogen
ions start diffusing into the mucous barrier quickly initiating
response, followed by HCl/pepsin that erodes the mucous barrier
injuring the surface epithelium and ﬁnally saline, which calms
down the reﬂux episode.
Esophageal Perfusion Catheter
Esophageal perfusion was performed with a specially
designed 6-channeled catheter manufactured by Wilson-Cook
Company (Chapel Hill, NC), as described in detail by Sarosiek
et al.21 Four larger diameter channels were used for infusion and
aspiration of the perfusate, gastric juice and incidentally swal-
lowed saliva, which is retained above the upper balloon. Two
smaller diameter channels were used for inﬂation of the upper
and lower balloons to compartmentalize the segment of the
lower esophagus.7,8,10,20–24
Perfusing Solutions
Esophageal perfusion in all subjects was performed
using fresh 10 mL solutions for each 1.5-minute interval: (1)
NaCl (0.15 M) that corresponds to 0.9% saline; (2) HCl (0.01
M; pH 2.1), this concentration and pH of HCl was chosen to
closely resemble the content of gastroesophageal reﬂuxate25,26;
and (3) HCl (0.01 M; pH 2.1) with pepsin, where pepsin (0.5
mg/mL; Sigma Chemical Co., St. Louis, MO) was dissolved in
the concentration that corresponds to the average proteolytic
activity of human gastric juice.27,28
Esophageal Perfusion Procedure
Subjects were placed in the semirecumbent left-sided
position. The nasopharynx was anaesthetized with xylocaine
gel, the esophageal catheter was inserted into the esophagus
through the nares and the balloons of the catheter were gently
insufﬂated to seal the esophageal lumen. This procedure allows
the compartmentalization of 3.75-cm segment of the esophagus
between the balloons.14,21,29,30 During each perfusion period of
1.5-minute interval, the entire 10 mL solution of perfusate was
circulated within the isolated segment of esophagus for a total
duration of 24 minutes for each subject. The ﬁnal value of each
perfusion represents the mean value of 4 consecutive 1.5-
minute intervals of perfusions or recirculations.
Analysis of Salivary Secretory Components
Salivary volume was assessed using a sialometer (Pro-
ﬂow Incorporated, Amityville, NY).8,20,22 Salivary pH was
monitored using the Expandable Ion Analyzer EA 940 (Orion
Res., Boston, MA).
The salivary bicarbonate and nonbicarbonate buffers
were analyzed by titration and back-titration methodology
using TitraLab 90 (Radiometer America Inc., Chicago, IL).31
Secretions form a thin ﬁlm on the mucosa and allows the
evolution of CO2 formed from acid-base interactions. There-
fore, the esophageal bicarbonate buffer value would be equil-
ibrated with CO2 tension of the lumen.
31,32 This was the
rationale for choosing titration to pH of 4.0 for the assessment
of esophageal bicarbonate in an open system (without cover-
ing with a layer of liquid parafﬁn oil) with continuous CO2-
free bubbling. The bicarbonate concentration was calculated
using the difference in the amount of acid initially required to
titrate the sample from its starting pH to pH 4.0 and the
amount of base required to back-titrate the sample to its orig-
inal pH after development of the CO2. The difference between
the back-titration from pH 4.0 to its original starting value and
the similar run of the buffer-free blank solution was used to
calculate nonbicarbonate buffers.31,32 In addition, this meth-
odology was always validated by the titration of known con-
centrations of bicarbonate and nonbicarbonate in the standard
solutions.
Salivary glycoconjugate (predominantly mucin) was
measured using the periodic–acid Schiff methodology.14,29,31
Salivary EGF was assessed by radioimmunoassay (RIA) using
a commercially available kit (Amersham, Arlington Heights,
IL).8,20,21,31
Salivary transforming growth factor alpha (TGF-a) was
recorded using a commercially available RIA kit based on
highly speciﬁc sheep anti-human TGF-a antibodies (Biomedi-
cal Technologies Inc., Stoughton, MA).31,33 The separation
between bound and unbound TGF-a was performed using don-
key anti-sheep IgG and polyethylene glycol. Human recombi-
nant TGF-a (BTI) was used for a standard curve. All samples
were centrifuged at 4°C and 3,000 rpm for 20 minutes, which
are the conditions required to spin down cellular debris, plasma
membrane sheets and nuclei.
Salivary prostaglandin E2 (PGE2) was measured using an
RIA kit (Amersham).30 This RIA method is based on highly
speciﬁc antibodies directed to oximated form of PGE2. Salivary
protein was monitored by the Lowry methodology.14
Data Processing and Statistical Analysis
Data were measured as mean values of salivary
collections at basal level, during paraﬁlm chewing, following
placement of tubing, following inﬂation of balloons and
during the perfusion intervals. All results were expressed as
mean 6 SEM. Statistical analysis by analysis of variance was
performed using S-Stat software (Jandel Scientiﬁc, San
Rafael, CA).
RESULTS
Salivary Inorganic Protective Components
Salivary volume in patients with NERD was signiﬁcantly
higher than control group (CTRL) during mechanical stimula-
tion with balloons (4.67 6 1.16 mL/min versus 3.16 6 0.32
mL/min, P , 0.05) and chemical stimulation with HCl/pepsin
and ﬁnal saline (4.12 6 0.38 mL/min versus 2.83 6 0.33 mL/
min, P , 0.05 and 4.39 6 0.54 mL/min versus 2.75 6 0.33
mL/min, P , 0.05, respectively), as shown in Figure 1. The
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bicarbonate output in the NERD group was signiﬁcantly higher
than the CTRL group during chemical stimulation with HCl/
pepsin (103.80 6 15.30 mEq/min versus 59.00 6 11.98 mEq/
min, P , 0.05) and ﬁnal saline (129.70 6 25.40 mEq/min
versus 48.40 6 10.39 mEq/min, P , 0.01), as shown in
Figure 2 (Table 1).
Salivary Organic Protective Components
The secretion of salivary glycoconjugate was signiﬁ-
cantly higher in the NERD group than the CTRL group
during mastication (3.24 6 0.86 mg/min versus 1.50 6 0.20
mg/min, P , 0.05), mechanical stimulation with balloons
(21.30 6 2.92 mg/min versus 12.67 6 1.59 mg/min, P ,
0.05) and during chemical stimulation with ﬁnal saline
(19.20 6 3.31 mg/min versus 11.19 6 1.65 mg/min, P ,
0.01), as shown in Figure 3. Mechanical stimulation with
balloons signiﬁcantly increased protein output in the NERD
when compared with the CTRL (13.40 6 2.68 mg/min versus
7.96 6 0.83 mg/min, P , 0.05). A similar phenomenon was
revealed during the chemical stimulation with ﬁnal saline
(9.64 6 1.04 mg/min versus 6.72 6 0.75 mg/min, P ,
0.05) (Table 2).
The salivary secretion of EGF in patients with NERD
was signiﬁcantly higher than controls during mechanical
FIGURE 1. Salivary volume output in the control group (CTRL) and patients with nonerosive reflux disease (NERD) (*P, 0.05, which is
significant). Salivary volume is significantly higher in patients with NERD during mechanical stimulation with balloons and chemical
stimulation with HCl/pepsin (acid/pepsin) and final NaCl (final saline).
FIGURE 2. Salivary bicarbonate output in the control group (CTRL) and patients with nonerosive reflux disease (NERD) (*P , 0.05 and
**P, 0.01, which is significant). Salivary bicarbonate secretion is significantly higher in patients with NERD during chemical stimulation
with HCl/Pepsin (acid/pepsin) and final NaCl (final saline).
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stimulation with balloons (11.40 6 4.76 ng/min versus
6.96 6 1.56 ng/min, P , 0.05). We observed higher TGF-
a output in the NERD than the CTRL group during mechan-
ical stimulation with tubing (0.40 6 0.13 ng/min versus
0.21 6 0.08 ng/min, P , 0.05) and chemical stimulation with
initial saline (0.49 6 0.12 ng/min versus 0.18 6 0.04 ng/min,
P , 0.05).
DISCUSSION
NERD is a distinct pattern of GERD characterized by
reﬂux-related symptoms in the absence of esophageal mucosal
erosions/breaks at conventional endoscopy.34 Patients with
NERD can be subdivided as follows based on etiology: (1)
NERD pH-positive patients with normal endoscopy and abnor-
mal distal esophageal acid exposure, (2) NERD patients with
TABLE 1. Salivary inorganic protective components in patients with NERD and CTRL (mean 6 SEM)
Parameter Basal Mastication Tubing Balloon
Volume in NERD (mL/min) 0.54 6 0.14 1.34 6 0.50 2.20 6 0.37 4.67 6 1.16*
Volume in CTRL (mL/min) 0.51 6 0.05 1.43 6 0.12 2.51 6 0.27 3.16 6 0.32
pH in NERD 7.23 6 0.17 7.67 6 0.17 8.07 6 0.21 7.98 6 0.16
pH in CTRL 7.14 6 0.09 7.63 6 0.08 8.02 6 0.06 7.93 6 0.09
Bicarbonate in NERD (mEq/min) 8.08 6 2.78 24.90 6 12.3 43.60 6 9.33 124.80 6 50.60
Bicarbonate in CTRL (mEq/min) 4.13 6 0.86 17.90 6 2.37 94.20 6 35.18 97.80 6 29.26
Nonbicarbonate in NERD (mEq/min) 6.96 6 1.79 6.93 6 2.02 17.70 6 4.00 27.40 6 15.20
Nonbicarbonate in CTRL (mEq/min) 4.42 6 1.07 11.60 6 1.60 18.10 6 3.99 19.10 6 4.43
Parameter Initial NaCl HCl HCl/pepsin Final NaCl
Volume in NERD (mL/min) 3.33 6 0.40 4.45 6 0.38 4.12 6 0.38* 4.39 6 0.54*
Volume in CTRL (mL/min) 2.94 6 0.29 3.68 6 0.41 2.83 6 0.33 2.75 6 0.33
pH in NERD 8.05 6 0.20 8.03 6 0.15 8.05 6 0.20 8.05 6 0.18
pH in CTRL 8.01 6 0.08 7.90 6 0.09 8.14 6 0.08 7.92 6 0.18
Bicarbonate in NERD (mEq/min) 92.60 6 16.30 87.90 6 21.72 103.80 6 15.30* 129.70 6 25.4**
Bicarbonate in CTRL (mEq/min) 72.50 6 16.30 77.90 6 11.82 59.00 6 11.98 48.40 6 10.39
Nonbicarbonate in NERD (mEq/min) 17.90 6 5.95 16.20 6 5.55 29.50 6 8.64 21.60 6 6.83
Nonbicarbonate in CTRL (mEq/min) 24.93 6 6.38 21.80 6 4.97 18.50 6 4.79 17.60 6 4.01
Values are presented as mean 6 SEM.
*P, 0.05 and **P, 0.01 respectively, signiﬁcant secretions of salivary inorganic protective components in patients with NERD when compared
with CTRL.
CTRL, control group; NERD, nonerosive reﬂux disease.
FIGURE 3. Salivary glycoconjugate output in the control group (CTRL) and patients with nonerosive reflux disease (NERD) (*P , 0.05
and **P , 0.01, which is significant). Salivary glycoconjugate secretion is significantly higher in patients with NERD during mastication,
mechanical stimulation with balloons and chemical stimulation with final NaCl (final saline).
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hypersensitive esophagus with normal endoscopy, normal
distal esophageal acid exposure and positive symptom associ-
ation for either acid (acid hypersensitive esophagus) or non-
acid reﬂux (non-acid hypersensitive esophagus) and (3)
patients with functional heart burn patients.35 The pathogene-
sis of NERD includes microscopic inﬂammation, visceral
hypersensitivity and sustained esophageal contractions. It
has been observed that acid exposure disrupts intracellular
connections in esophageal mucosa, producing dilated intercel-
lular spaces and increasing esophageal permeability, allowing
reﬂuxed acid to penetrate the submucosa and reach chemo-
sensitive nociceptors causing symptoms. Peripheral receptors
are shown to be mediating esophageal hypersensitivity
because of acid reﬂux including upregulation of acid sensing
ion channels.34
The integrity of the esophageal mucosa depends on an
equilibrium between aggressive factors (acid, pepsin and bile
components) and defense mechanisms.7,12,14,16,20,23,29,33,36 Esoph-
ageal mucosal defense mechanisms operate as 3 complementary
barriers: pre-epithelial, epithelial and post-epithelial.10,12,36 It has
been demonstrated recently that salivary bicarbonate secre-
tion is signiﬁcantly higher up to 3-folds when the upper
esophageal mucosa was exposed to acid and pepsin, leading
to its better protection when compared with salivary secre-
tory response during exposure to acid and pepsin of lower
esophageal mucosa.36 Marcinkiewicz et al31 previously dem-
onstrated an increase in esophageal mucosal secretory pro-
tective factors in patients with NERD. This study focuses on
the salivary secretory components of the pre-epithelial bar-
rier in patients with NERD as a vanguard of mucosal
protection.
Current insight shows that the secretion of salivary
protective components may be important in prevention of the
development of endoscopic mucosal damage. Salivary volume
dilutes intraluminal acid and pepsin originating from the
gastroesophageal reﬂuxate.17 Glycoconjugate has a protective
role by retarding hydrogen ion diffusion through and to pro-
vide an architectural framework for the unstirred layer of the
mucus bicarbonate barrier.19,37 The EGF and TGF-a bind to
the same receptor located on the apical domain of esophageal
squamous epithelium, participating in the proliferation and
differentiation of the esophageal epithelium.38 EGF is also
related to esophageal and gastric mucosal repair of the alimen-
tary tract injury.11
It was demonstrated by Rourk et al20 that patients
with RE exhibited a signiﬁcant impairment not only in the
secretion of salivary EGF but also esophageal EGF.39
Namiot et al29 also demonstrated a decline in esophageal
mucin secretion in patients with RE. The esophageal muco-
sal protection is contributed by 2 factors: (1) the secretion of
salivary protective factors by salivary glands that ﬂows
through esophagus and (2) the local secretion of protective
factors by submucosal mucous glands of esophagus itself.
Patients with NERD were found to have strong secretions of
salivary protective factors demonstrated by this study as
well as esophageal protective factors studied previously by
Marcinkiewicz et al.31 This double protection in patients
with NERD might prevent or delay the progression to Bar-
rett’s esophagus and esophageal adenocarcinoma (Figure 4).
The simple way to help patients is to achieve stronger sal-
ivary secretion by chewing a sugarless gum through masti-
catory stimulation, which suggests its potential value as
TABLE 2. Salivary organic protective components in patients with NERD and CTRL
Parameter Basal Mastication Tubing Balloon
Glycoconjugate NERD (mg/min) 0.76 6 0.25 3.24 6 0.86* 8.34 6 2.48 21.30 6 2.92*
Glycoconjugate CTRL (mg/min) 0.75 6 0.08 1.50 6 0.20 8.30 6 0.99 12.67 6 1.59
Protein in NERD (mg/min) 1.68 6 0.42 4.82 6 1.44 5.57 6 0.94 13.40 6 2.68*
Protein in CTRL (mg/min) 1.77 6 0.26 3.47 6 0.44 6.69 6 0.72 7.96 6 0.83
EGF in NERD (ng/min) 1.43 6 0.41 2.28 6 0.69 4.66 6 0.66 11.40 6 4.76*
EGF in CTRL (ng/min) 0.66 6 0.11 1.30 6 0.18 3.16 6 0.66 6.96 6 1.56
TGF-a in NERD (ng/min) 0.21 6 0.15 0.11 6 0.04 0.40 6 0.13* 0.53 6 0.19
TGF-a in CTRL (ng/min) 0.08 6 0.03 0.20 6 0.07 0.21 6 0.08 0.28 6 0.05
PGE2 in NERD (pg/min) 81.40 6 29.20 250.00 6 75.90 241.00 6 55.70 278.00 6 71.40
PGE2 in CTRL (pg/min) 65.20 6 13.90 179.00 6 50.40 182.00 6 38.60 246.00 6 58.30
Parameter Initial NaCl HCl HCl/pepsin Final NaCl
Glycoconjugate NERD (mg/min) 14.52 6 3.38 16.50 6 4.09 16.10 6 3.77 19.20 6 3.31**
Glycoconjugate CTRL (mg/min) 11.68 6 1.68 9.16 6 1.32 11.75 6 1.70 11.19 6 1.65
Protein in NERD (mg/min) 8.20 6 1.29 10.70 6 1.27 10.20 6 1.59 9.64 6 1.04*
Protein in CTRL (mg/min) 7.60 6 0.89 8.75 6 1.06 7.11 6 0.88 6.72 6 0.75
EGF in NERD (ng/min) 5.63 6 1.65 8.54 6 2.09 6.62 6 1.96 8.44 6 2.15
EGF in CTRL (ng/min) 5.01 6 1.23 4.86 6 0.95 5.77 6 1.81 6.58 6 1.92
TGF-a in NERD (ng/min) 0.49 6 0.12* 0.37 6 0.11 0.26 6 0.07 0.35 6 0.09
TGF-a in CTRL (ng/min) 0.18 6 0.04 0.22 6 0.04 0.24 6 0.06 0.17 6 0.03
PGE2 in NERD (pg/min) 328.00 6 81.00 243.00 6 59.00 225.00 6 57.0 155.00 6 30.40
PGE2 in CTRL (pg/min) 161.00 6 30.90 165.00 6 62.50 230.00 6 94.7 146.00 6 36.40
Values are presented as mean 6 SEM.
*P , 0.05 and **P , 0.01 respectively, signiﬁcant secretions of salivary organic protective components in patients with NERD when compared
with CTRL.
CTRL, control group; NERD, nonerosive reﬂux disease.
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a therapeutic approach to the treatment of patients with
GERD.23
As per this study, patients with NERD demonstrated an
increase in salivary volume during mechanical and chemical
stimulations and bicarbonate during chemical stimulation,
mediated by vagovagal neural reﬂex so-called esophagosali-
vary reﬂex. This stronger salivary ﬂow might potentially
neutralize acid/pepsin, providing protection. Patients with
NERD also showed higher secretions of salivary glycoconju-
gates (mucin), protein and TGF-a during intraesophageal
mechanical and chemical stimulation than controls. It was also
found that EGF output during intraesophageal mechanical
stimulation by balloons was more than 60% higher in patients
with NERD than controls. An important point to note in the
current data analysis was that both NERD and CTRL groups
showed an increase in the secretions of salivary components
during mechanical and chemical stimulations from baseline,
but salivary secretions were signiﬁcantly higher in patients
with NERD than controls. Current data provided new evi-
dence that signiﬁcantly higher secretions of inorganic and
organic salivary protective components might quantitatively
and qualitatively enhance the protective potential of the
mucus/bicarbonate layer covering the esophageal mucosa in
patients with NERD.
CONCLUSIONS
Patients with NERD demonstrated a signiﬁcantly
stronger salivary secretory response in terms of volume,
bicarbonate, glycoconjugate, protein, EGF and TGF-a
than asymptomatic controls. This enhanced salivary esoph-
agoprotection is potentially mediating resistance to the
development of endoscopic mucosal changes by gastro-
esophageal reﬂux.
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